The institute has developed an approach in which corn is genetically modified to produce a non-infectious hepatitis B virus-like particle that can be made into an edible wafer when mixed with flour, sugar and water.
The corn processing technique was associated with an immune response in mice that is four times the response to injected vaccines, according to the study.
The materials used to create each wafer cost less than 1 cent, and the vaccine can be administered without medical staff. The new wafer vaccine would not require refrigeration and would cost less than $1 to manufacture each dose.
The Applied Biotechnology Institute believes it will receive Food and Drug Administration approval to start human trials of the corn-based hepatitis B vaccine within the next year.
More articles on hepatitis:
WHO issues first hepatitis B treatment guidelines
Study seeks to determine if provider type influences hepatitis C treatment outcomes
Hep C transmission during routine surgeries highlights need for tight infection control
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.